{
    "clinical_study": {
        "@rank": "127704", 
        "arm_group": {
            "arm_group_label": "temozolomide, endostatin", 
            "arm_group_type": "Experimental", 
            "description": "Endostatin 15mg/d\uff0cIV infusion, d1-d14 Temozolomide 150-200mg/m2/d\uff0cp.o., d1-d7\u3002 Repeat every 3 weeks."
        }, 
        "brief_summary": {
            "textblock": "Temozolomide combined with endostatin have efficacy in well-differentiated pancreatic\n      neuroendocrine tumor"
        }, 
        "brief_title": "Temozolomide Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor", 
        "condition": "Advanced Well-differentiated Pancreatic Neuroendocrine Tumor", 
        "condition_browse": {
            "mesh_term": [
                "Neuroendocrine Tumors", 
                "Adenoma, Islet Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 years of age and older\n\n          2. ECOG \u22642\n\n          3. Pathologically confirmed locally advanced or metastatic well-differentiated\n             pancreatic neuroendocrine tumor\uff08G1,G2\uff09\n\n          4. Prior treatment with one-line chemotherapy is allowed, with the exception of prior\n             treatment with temozolomide or dacarbazine or endostatin within the past 6 months\n\n          5. Disease progressed during or after last therapy\n\n          6. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of\n             all prior systemic anticancer therapy\n\n          7. Disease progressed within the past 12 months\u3002\n\n          8. Patients must have at least one measurable site of disease according to RECIST1.1\n             criteria that has not been previously irradiated.\n\n          9. Adequate bone marrow, liver and renal function\n\n         10. Life expectancy 3 months or more\n\n         11. Patient informed consent\u3002\n\n        Exclusion Criteria:\n\n          1. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine\n             tumor.\n\n          2. 2 or more lines of prior chemotherapy\u3002\n\n          3. Patients who have any severe and/or uncontrolled medical conditions or other\n             conditions that could affect their participation in the study\n\n          4. Uncontrolled infectious disease\u3002\n\n          5. Other malignancies within the past 5 years except for adequately treated carcinoma of\n             the cervix or basal or squamous cell carcinoma of the skin\n\n          6. Uncontrolled brain or leptomeningeal metastases\n\n          7. Patients with known hypersensitivity to temozolomide or endostatin\u3002\n\n          8. Patient could not take tablets\u3002"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845675", 
            "org_study_id": "TEPNET"
        }, 
        "intervention": {
            "arm_group_label": "temozolomide, endostatin", 
            "intervention_name": "temozolomide combined with endostatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine", 
                "Endostatins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "temozolomide", 
            "endostatin", 
            "advanced", 
            "well-differentiated", 
            "pancreatic neuroendocrine tumor"
        ], 
        "lastchanged_date": "November 16, 2013", 
        "location": {
            "contact": {
                "email": "cnchengyuejuan@yahoo.com", 
                "last_name": "Yuejuan Cheng, M.D.", 
                "phone": "861069158315"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100730"
                }, 
                "name": "Division of Medical Oncology, Peking Union Medical College Hospital"
            }, 
            "investigator": {
                "last_name": "Yuejuan Cheng, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "cnchengyuejuan@yahoo.com", 
            "last_name": "Yuejuan Cheng, M.D.", 
            "phone": "861069158315"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845675"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "YueJuan Cheng", 
            "investigator_title": "attending medical oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "From date of treatment until the date of death,  assessed up to 5 years"
        }, 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}